

AUG. 26. 2003 4:18PM

GLAXO WELLCOME

NO. 0298 P. 1

FAX



GlaxoSmithKline

To Group 1624
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Allyson K. Jacobs
.....
Tel 919-483-9105 Fax 919-483-7988
.....
E-mail aki27836@glaxowellcome.com
.....
Date 26-Aug-2003 Pages including cover 22
.....
Subject Serial No.: 10/071,358
.....
Filing Date: 2/8/02
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Terminal Disclaimer + copy
Amendment Transmittal
Response
Supplemental IDS + copy
Supplemental PTO 1449
Certificate of Transmission


FAX RECEIVED

AUG 27 2003

GROUP 1600

OFFICIAL

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PG3416US2	
Applicant(s): Carter et al.					
Serial No. 10/071,358	Filing Date 2/8/02	Examiner T. Truong	Group Art Unit 1624		
Invention: HETEROCYCLIC COMPOUNDS					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST #. PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	27 -	36 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
 <div style="display: flex; justify-content: space-between;"><div><input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div><div style="text-align: right;">Dated: August 26, 2003</div></div> <div style="margin-top: 20px;"><div style="display: flex; justify-content: space-between;"><div style="width: 60%;"> Signature John L. Lemanowicz, Reg. 37,380 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398</div><div style="width: 35%; border: 1px solid black; padding: 5px;"><div style="text-align: center;">I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</div><div style="text-align: center; margin-top: 20px;">Signature of Person Mailing Correspondence</div><div style="text-align: center; margin-top: 20px;">Typed or Printed Name of Person Mailing Correspondence</div></div></div><div style="margin-top: 20px;">CC:</div></div>					

P111LARGE/REV06

